Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.

Sponsor
Anna Cruceta
Study ID
NCT02109315
Phase
PHASE1
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Vitamine C — DRUG
    C Vitamine endovenous 1000 mg/5 ml. Infusion dose: 30 mgr/min
  • Liraglutide 6 mg — DRUG
    Liraglutide endovenous de 0.6 mg. one time a day

Study Details

To investigate the effect of liraglutide on vascular injury induced hypoglycemia in patients with type 1 diabetes mellitus. The vascular damage is evaluated at investigating the changes of endothelial function

Key Dates

Start date
May 31, 2014
Status verified
Apr 2014
Primary completion
May 31, 2015
Completion
May 31, 2015

Study Design

Enrollment
0 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Liraglutide endovenous 6 mg
    Liraglutide endovenous de 0.6 mg. one time a day
  • Experimental: Vitamine C
    C Vitamine endovenous 1000 mg/5 ml. Infusion dose: 30 mgr/min

Primary Outcome Measure

Endothelial dysfunction (Flow mediated dilation): Endothelial function is assessed measuring flow-mediated vasodilation (FMD) of the brachial artery. [ Time Frame: 8 weeks ]

Related Studies